What does Alphabiome do?
Alphabiome is pioneering advanced biotechnology to extract genetic biomarkers from microbial DNA using a proprietary AI model. The company decodes complex microbiome patterns to predict drug efficacy and drive precision medicine.
How much did they raise?
The company raised $8M in a Seed round, led by AIX Ventures, with additional participation from other investors.
What are their plans for the money?
With the new funds, Alphabiome aims to expand its operations and enhance its R&D efforts, potentially accelerating breakthroughs in the identification of novel biomarkers for precision medicine.
What have they achieved so far?
Alphabiome has demonstrated promising progress by successfully conducting trials on microbiome samples from Ulcerative Colitis and Crohn's patients, identifying over 10,000 complex microbe-derived biomarkers.
